Abstract CD26, a membrane-bound ectopeptidase, is known as an activated T cell marker with dipeptidyl peptidase IV (DPPIV) activity that has diverse functional roles in the regulation of peptide hormones, neuropeptides, chemokines and growth factors. We recently isolated a novel inhibitor of DPPIV, sulphostin, from culture broth of Streptomyces sp. MK251-43F3. We investigated herein the hematopoietic effect of sulphostin in mice and found that sulphostin induced the production of granulocyte colony-stimulating factor (G-CSF), stimulated myeloblasts in bone marrow, and increased neutrophil numbers in peripheral blood in both normal mice and mice with cyclophosphamide-induced leucopenia. Sulphostin desulfonate, in addition to sulphostin, has a similar inhibitory effect on DPPIV and stimulatory effect on neutrophils. These results suggest that DPPIV/CD26 might be a novel target for hematopoietic stimulation and DPPIV inhibitors including sulphostin and derivatives may be candidates for further development.
Introduction
Dipeptidyl peptidase IV (DPPIV, E.C.3.4.14.5) is a protease with a homodimer type II membrane protein, which is highly expressed on the surface of endothelial and immune cells and identical to CD26 antigen [1] . The cDNA for human DPPIV/CD26 encodes a protein of 766 amino acids with 9 potential glycosylation sites. DPPIV/CD26 consists of three extracellular regions; a membrane-proximal glycosylated region starting with a 20-amino acid flexible stalk region, a cysteine-rich region, and a 260-amino acid C-terminal region with DPPIV activity. DPPIV removes Nterminal dipeptides from a number of proteins having either a Pro or Ala residue in the penultimate position. DPPIV/CD26 regulates the activity of many peptide hormones, neuropeptides, cytokines and growth factors via its peptidase function [2] . On the other hand, the surface protein DPPIV/CD26 is capable of mediating cell-matrix and cell-cell contact through interactions with other molecules or proteins probably including collagen, fibronectin, and adenosine deaminase. Recently, it was described as a co-stimulatory molecule in T cell activation and reportedly associated with CD45. DPPIV/CD26 is involved in regulating the proliferation of the same hematopoietic and T cell-lineage, and associated with HIV pathogenesis. Experimental models and clinical studies addressing the role of these enzymes and the effect of specific inhibitors have paved the way to novel therapeutic concepts in immunology [3] , oncology [4] , diabetes [5] and so on.
Sulphostin was first isolated from the culture broth of Streptomyces sp. MK251-43F3 as a novel inhibitor of DPPIV [6] . Here we show that sulphostin has G-CSFinducing activity and increases neutrophil numbers in peripheral blood in mice.
Materials and Methods

Mice
Male ICR mice, 7 weeks of age, were supplied from Charles River Japan, Inc., Kanagawa, Japan. They were kept under specific pathogen-free conditions with clean air of our animal facility. The animal care and use were in accordance with institutional guidelines.
Agents
Sulphostin (configuration of C-3 and P is S and R, respectively), P-epi sulphostin (configuration of C-3 and P is S and S, respectively) and a sulfonic acid group-deficient analogue (sulphostin desulfonate) were synthesized as reported previously [7, 8] . Val-boroPro (PT-100) was synthesized by the method as reported by Coutts et al. [9] . The structures are shown in Fig. 1 . The agents were dissolved in saline solution and filtered with a Millipore filter (0.22 mm). All agents and experiments contained less than 0.1 ng/ml of endotoxin as assessed with the Limulus lysate assay.
Measurement of DPPIV Inhibitory Activity
The in vitro assay for DPPIV inhibitory activity was performed as reported previously [7] . Briefly, 0.1 M Tris (hydroxymethyl)-aminomethane/maleic acid buffer solution (pH 7.2, 100 ml), 3.2 mM Gly-Pro-b-naphthylamide (25 ml, Bachem, Switzerland), and an aqueous solution (50 ml) of the agents were added into 96-well micro plates. The resultant solution was warmed for 10 minutes at 37°C, and then the DPPIV solution (25 ml) was added to the solution. The combined solution was allowed to react for 1 hour at 37°C. The reaction was terminated by adding a solution (100 ml) of 0.2% Fast Garnet GBC salt (Sigma, U.S.A.) in 0.5 M sodium citrate buffer solution (pH 3.78) including 10% polyoxyethylene sorbitan monolaurate (Wako, Japan). The absorbance at 525 nm was measured.
Sulphostin Treatment ICR mice were intravenously administered saline or sulphostin daily as indicated. In the leukopenic model, ICR mice received an intraperitoneal injection of cyclophosphamide (CP) at 200 mg/kg on day 0 and were intravenously administered saline or sulphostin daily starting on day 1 as indicated in the figure legend.
Peripheral blood was collected from the abdominal or orbital vein in the treated mice on a predetermined day for the determination of blood cell counts, changes in segmented neutrophils and cytokine production.
Hematology
The absolute number of white blood cells was counted using an automatic blood cell counter (MEK-6258, Nihon Kohden Co., Tokyo) and the proportion of segmented neutrophils was determined in blood smears with the Wright Stain (Sigma).
Cytokine ELISA Levels of G-CSF, IFNg and IL12 were determined by quantikine enzyme linked immunosorbent assay (ELISA) according to the attached product information (R&D Systems, Minneapolis, MN).
Histopathological Examination
The tissues including bone marrow, spleen, thymus and liver were embedded in paraffin, sectioned and stained with hematoxylin with eosin. Histopathological observations were conducted.
Statistics
The student t test and parametric Williams test were calculated using Microsoft Excel software (Richmond, WA).
Results
Inhibition of DPPIV Activity by Sulphostin and Related Compounds
Sulphostin and the related desulfonate strongly inhibit DPPIV activity similar to that by Val-boroPro (PT-100). The 50% inhibitory concentrations (IC 50 ) of sulphostin and the related desulfonate were 21 and 94 nM, respectively, although P-epi sulphostin did not show any inhibitory activity (Table 1) . 
Increase in the Absolute Number of Neutrophils by Sulphostin
The effect of sulphostin on hematopoiesis was explored in mice, when sulphostin was intravenously administered to ICR mice at a dose of 2 mg/kg to 250 mg/kg for 5 consecutive days (Fig. 2) . Sulphostin dose-dependently increased the absolute number of white blood cells in peripheral blood and the increase was significant at a dose over 10 mg/kg of sulphostin. There were no decreases of body weight or abnormal clinical signs in mice observed following sulphostin administration even at 250 mg/kg. All mice were autopsied 24 hours after the last administration. Spleen weights had also doubled in sulphostin-treated mice in comparison with those in saline-treated mice. When sulphostin was administered at doses of 50 or 250 mg/kg (data not shown), liver weights were increased about 20% in comparison with those in saline-treated mice. These results suggest that sulphostin stimulated hematopoiesis not only in bone marrow but also in the spleen and liver.
Cytokine Production and Histopathological Examination
To examine the precise stimulation of hematopoiesis, sulphostin was intravenously administered at a dose of 30 mg/kg for three days and the absolute number of segmented neutrophils and level of cytokines were measured. As shown in Fig. 3A , the absolute number of segmented neutrophils began to increase 12 hours after the third administration of sulphostin and peaked 24 hours after the administration. Coincidently, the G-CSF concentration in blood significantly increased 24 hours after the third administration (Fig. 3B) . Although sulphostin stimulated IFNg production, the increase was not significant. There P-epi sulphostin Ͼ1000
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Val-boroPro 7.4 DPPIV activity was measured by degradation of Gly-Pro-bnaphthylamine as reported previously [7] . was no stimulation of IL12 production observed in the experiment (data not shown). Further, the histopathological confirmation was independently conducted under the same schedule of sulphostin administration in Fig. 3 in mice (Table 2) . Histopathological examination showed an increase in the number of myeloblasts in bone marrow, an increase in the number of myeloblasts and megakaryocytes in the red pulp of spleen, thinning of the cortex in thymus and an increase in the number of myeloblasts 24 hours after the second and third administrations of sulphostin. Representative specimens of bone marrow are shown in Fig. 4 .
Stimulation of bone marrow recovery in cyclophosphamide-induced leucopenia
Finally the effect of sulphostin and the related desulfonate on hematopoietic recovery following treatment with myelosuppressive dose of cyclophosphamide was examined (Fig. 5 ). Mice injected with cyclophosphamide at a dose of 200 mg/kg showed a reduction of segmented neutrophils 4 days after cyclophosphamide injection. Sulphostin and the related desulfonate both at a dose of 30 mg/kg showed a tendency to stimulate the recovery of hematopoiesis in mice with cyclophosphamide-induced leucopenia. The desulfonate at a dose of 100 mg/kg showed significant stimulation of recovery. However, P-epi sulphostin did not show any stimulation of bone marrow corresponding to the inhibition of DPPIV (data not shown).
Discussion
The present study demonstrated that sulphostin, a potent inhibitor of DPPIV, has a stimulating effect on the increase in myeloblasts in bone marrow, absolute number of neutrophils and production of G-CSF in mice. Sulphostin desulfonate inhibits DPPIV activity and increases neutrophil numbers similar to sulphostin. However, P-epi sulphostin shows no enzyme inhibition or stimulation of myelogenesis. As reported previously, sulphostin, originally isolated from the cultured broth of Streptomyces, was synthesized as three possible stereoisomers whose absolute configurations at C3 and the phosphorus atom were determined to be S and R, respectively, while those of P-epi sulphostin are S and S, respectively [7] . This result suggests that the configuration of the phosphorus atom is primarily responsible for the inhibitory activity toward DPPIV. Recently we examined the interaction of sulphostin with the catalytic site of DPPIV and found that all the functional groups on the piperidine ring are crucial to the inhibitory effect of sulphostin on DPPIV, and that the sulfonic acid group, which constructs the amino(sulfoamino)phosphinyl group, contributed to the stability of the compounds [8] . Moreover, those functional groups must be adjoined to the piperidine ring for the inhibitory activity. The size of the nitrogen-containing heterocyclic ring including piperidine appeared to scarcely affect the activity. Therefore, the mechanism behind the relationship between DPPIV inhibition and bone marrow stimulation aroused our interest. Sulphostin (30 mg/kg) was intravenously administered to ICR mice once a day for 3 consecutive days. Mice were sacrificed at the indicated hours after administration and histopathological study was examined in specimens prepared from sulphostin-treated mice (nϭ3).
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CD26/DPPIV (EC 3.4.14.5) is a 110-Kda glycoprotein expressed in various cell types tissues such as renal proximal tubules, intestinal epithelial cells, kidney, liver, placenta and lung. The complete c-DNA and derived amino acid sequence was published in 1992 [10] and the threedimensional crystal structure analysis was determined in 2003 [11] . CD26 is reported to be a marker of autoimmune disease, adenosine deaminase deficiency and HIV pathogenesis. Interestingly, insulin secretion was enhanced and glucose tolerance was improved in mice lacking CD26 [12] . Thus, a variety of DPPIV/CD26 inhibitors have been found and developed for the treatment of type 2 diabetes, as immunosuppressants and hematopoietic stimulators [13] . For instance, Diprotin A (Ile-Pro-Ile), a 1st generation of inhibitor [14] , Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide showed inhibitory activity against T cells [15] . LAF237 and MK-0431 showed inhibition of GLP-1 (glucagon-like peptide-1), and are under Phase II clinical trials in patients with type 2 diabetes [16] .
CD26/DPPIV truncated various biologically active peptides. Guan et al. observed that the full-length MIP-1b is processed by CD26/DPPIV to the truncated form and that cleavage can be blocked by DPPIV inhibitory peptides derived from HIV Tat or thromboxane A2 receptor [17] . CD26/DPPIV has the ability to cleave the chemokine CXCL12/SDF-1a (stromal cell derived factor 1a ) at its two prolines. CD26/DPPIV co-distributes and coimmunoprecipitates with CXCR4, a receptor for CXCL12/ SDF-1a, suggesting a functional relationship with SDF-1 [18] . Broxmeyer et al. reported that CXCL12/SDF-1a chemoattracts hematopoietic stem and progenitor cells (HSC/HPC) and may play a crucial role in the mobilization of HSC/HPC from the bone marrow (BM) [3, 19] . Table 2 , magnification ϫ15. CD26/DPPIV cleaves dipeptides from the N-terminus of polypeptide chains, including CXCL12. CD26 is expressed in normal Sca-1 ϩ ckit ϩ lin Ϫ HSC/HPC isolated from mouse BM and these cells possess CD26 peptidase activity. Recently, it was reported that the inhibition by a DPPIV inhibitor of Diprotin A treatment or genetic deletion of CD26 in CD26 Ϫ/Ϫ mice with donor stem cells increased the efficacy of hematopoietic stem cell transplantation about 10 fold. It was hypothesized that CXCL12, which is thought to be involved in the homing of stem cells, was a target of CD26 inhibition which might increase stem cell homing and engraftment [3] . Although G-CSF is not truncated by CD26/DPPIV, other cytokines or chemokines including MIP-1 chemotaxis factor of neutrophils, SDF-1 stimulation factor for hematopoiesis, and others may be involved in the mechanism [12] . CXCR4 is important for mediating the specific migration of bone marrow stromal cells to bone marrow.
On the other hand, Pro-boroPro, well known as a CD26 inhibitor, has similar activity to sulphostin and reportedly stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation [20] . The related analogue of PT-100 (Val-boroPro) showed bone marrow stimulatory activity and anti-tumor activity [21] , and a clinical study is ongoing in oncology. However, Jones et al. reported that PT-100 was activated to increase WBC cell numbers in CD26 Ϫ/Ϫ knock out mice. Thus, PT-100-associated effects occur via a CD26/DPPIV-independent pathway. They suggested that the hematopoietic target for PT-100 is fibroblast activation protein (FAP) [22] . FAPa is a 95 Kda surface antigen selectively expressed in reactive stromal fibroblasts of epithelial cancer, granulation tissue of healing wounds and malignant cells of bone and soft-tissue sarcoma [23, 24] . FAPa showed 48% amino acid sequence identity to the CD26/DPPIV. However, CD26 is widely expressed in normal tissues. It is reported that FAPb is identical to CD26, and FAPa and FAPb (CD26/DPPIV) closely interact [23] . Further study is needed to clarify the mechanism of bone marrow stimulation by sulphostin and whether the target molecule of sulphostin is CD26/ DPPIV or not. In summary, sulphostin induces the production of cytokines including G-CSF and stimulates myeloblasts in bone marrow. Our preliminary data indicate that sulphostin and its derivatives have therapeutic potential as a strong inhibitor of DPPIV.
